Physician profile
Katia E Taba
NPI 1376768242
$5,117.38
in general payments reported to CMS, 2019-2025
22 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 79% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $206 · 2021: $582 · 2022: $890 · 2023: $991 · 2024: $805 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,161 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.72 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $901.79 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $703.47 | 2022-2025 | Syfovre |
| Astellas Pharma US INC | $554.61 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $533.83 | 2021-2023 | Iluvien |
| Genentech USA, INC. | $520.42 | 2020-2025 | Vabysmo, Susvimo |
| Abbvie INC. | $271.56 | 2022-2024 | Ozurdex |
| Allergan, INC. | $247.03 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $216.39 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $161.62 | 2022 | |
| Notal Vision, INC. | $143.28 | 2025 | Foresee Home |
| Bausch & Lomb Americas INC. | $130.54 | 2022-2023 | Miebo, Xiidra |
| Eyepoint US, INC. | $124.97 | 2022 | |
| Kala Pharmaceuticals, INC. | $105.46 | 2019-2021 | |
| Biotissue Holdings INC. | $103.55 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $91.71 | 2019-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $86.35 | 2022 | |
| Sun Pharmaceutical Industries INC. | $62.24 | 2024-2025 | |
| Coherus Oncology, INC. | $56.04 | 2023-2024 | |
| Lumibird Medical INC. | $37.71 | 2022 | |
| Oyster Point Pharma, INC. | $25.35 | 2022 | |
| Ani Pharmaceuticals, INC. | $23.18 | 2025 | Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katia Taba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.